Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KRAS wild-type
i
Other names:
KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3845
Related biomarkers:
Expression
Mutation
CNA
Others
‹
STK11 deletion + KRAS mutation (6)
KRAS G12C + PD-L1 overexpression (4)
KRAS mutation + PD-L1 expression (4)
CPS1 overexpression + KRAS mutation + STK11 mutation (3)
HER-2 amplification + KRAS G12D (3)
KEAP1 deletion + KRAS mutation (3)
PD-L1 overexpression + KRAS mutation (3)
EGFR exon 19 deletion + KRAS mutation (2)
KRAS G12C + PD-L1 underexpression (2)
KRAS mutation + PD-L1 negative (2)
MSI-L/dMMR + KRAS G12V (2)
AXL overexpression + KRAS G12C (1)
CDH2 overexpression + KRAS wild-type (1)
Chr t(11;14) + KRAS mutation (1)
EGFR C797S + KRAS amplification + RB1 deletion (1)
EGFR L858R + KRAS amplification + RB1 deletion (1)
EGFR T790M + KRAS amplification + RB1 deletion (1)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)
EGFR exon 19 deletion + TP53 mutation + CDK6 amplification + KRAS amplification (1)
EGFR expression + KRAS G12C (1)
EGFR overexpression + KRAS 13D (1)
EGFR overexpression + KRAS mutation (1)
FGFR1 overexpression + KRAS G12C (1)
GNA13 deletion + KRAS mutation (1)
GOPC-ROS1 fusion + KRAS Q61H (1)
HER-2 amplification + KRAS exon 2 wild-type (1)
HER-2 amplification + KRAS wild-type (1)
HER-2 overexpression + KRAS wild-type (1)
IGF1R overexpression + KRAS mutation (1)
IR overexpression + KRAS mutation (1)
IRS2 amplification + KRAS mutation (1)
KEAP1 mutation + KRAS wild-type (1)
KRAS A146 + TMB-H (1)
KRAS G12C + PD-L1 expression (1)
KRAS G12C + PD-L1 underexpression + STK11 mutation (1)
KRAS G12D + Chr del(9)(p21) (1)
KRAS G12D + HER-2 amplification + TMB-H (1)
KRAS G12D + TP53 deletion (1)
KRAS amplification + BRAF wild-type (1)
KRAS amplification + RAS wild-type (1)
KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)
KRAS mutation + BCL2A1 overexpression (1)
KRAS mutation + CDK9 overexpression + HR positive (1)
KRAS mutation + EGFR amplification (1)
KRAS mutation + ER expression (1)
KRAS mutation + HER-2 positive (1)
KRAS mutation + HR positive (1)
KRAS mutation + PD-L1 underexpression (1)
KRAS mutation + PIK3CA wild-type (1)
KRAS mutation + PTPN11 overexpression (1)
KRAS mutation + TP53 mutation + GNA13 deletion (1)
KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)
KRAS mutation + YKL-40 overexpression (1)
KRAS wild-type + BRAF V600E (1)
KRAS wild-type + NRAS wild-type + MSI-H/dMMR (1)
KRAS mutation + STK11 mutation + AXL expression (1)
MLL-AFF1 fusion + KRAS mutation (1)
MSI-H/dMMR + KRAS G12D (1)
MSI-H/dMMR + KRAS Mutation (1)
MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)
MTAP deletion + KRAS G12C (1)
PD-L1 negative + KRAS G12C (1)
PD-L1 overexpression + KRAS G12C + TP53 mutation (1)
POMK-NRG1 fusion + KRAS mutation (1)
POMK‐NRG1 fusion + KRAS G12D (1)
PTEN deletion + KRAS G12C (1)
RET positive + KRAS G12V (1)
ROS1 fusion + KRAS G12C (1)
STK11 mutation + KRAS mutation + TP53 deletion (1)
STRN-ALK fusion + KRAS G13D (1)
TP53 S12F + KRAS G12D + TMB-L (1)
HER-2 amplification + KRAS G12C (0)
PRMT5 overexpression + KRAS mutation (0)
STK11 deletion + KRAS mutation (6)
KRAS G12C + PD-L1 overexpression (4)
KRAS mutation + PD-L1 expression (4)
CPS1 overexpression + KRAS mutation + STK11 mutation (3)
HER-2 amplification + KRAS G12D (3)
KEAP1 deletion + KRAS mutation (3)
PD-L1 overexpression + KRAS mutation (3)
EGFR exon 19 deletion + KRAS mutation (2)
KRAS G12C + PD-L1 underexpression (2)
KRAS mutation + PD-L1 negative (2)
MSI-L/dMMR + KRAS G12V (2)
AXL overexpression + KRAS G12C (1)
CDH2 overexpression + KRAS wild-type (1)
Chr t(11;14) + KRAS mutation (1)
EGFR C797S + KRAS amplification + RB1 deletion (1)
EGFR L858R + KRAS amplification + RB1 deletion (1)
EGFR T790M + KRAS amplification + RB1 deletion (1)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)
EGFR exon 19 deletion + TP53 mutation + CDK6 amplification + KRAS amplification (1)
EGFR expression + KRAS G12C (1)
EGFR overexpression + KRAS 13D (1)
EGFR overexpression + KRAS mutation (1)
FGFR1 overexpression + KRAS G12C (1)
GNA13 deletion + KRAS mutation (1)
GOPC-ROS1 fusion + KRAS Q61H (1)
HER-2 amplification + KRAS exon 2 wild-type (1)
HER-2 amplification + KRAS wild-type (1)
HER-2 overexpression + KRAS wild-type (1)
IGF1R overexpression + KRAS mutation (1)
IR overexpression + KRAS mutation (1)
IRS2 amplification + KRAS mutation (1)
KEAP1 mutation + KRAS wild-type (1)
KRAS A146 + TMB-H (1)
KRAS G12C + PD-L1 expression (1)
KRAS G12C + PD-L1 underexpression + STK11 mutation (1)
KRAS G12D + Chr del(9)(p21) (1)
KRAS G12D + HER-2 amplification + TMB-H (1)
KRAS G12D + TP53 deletion (1)
KRAS amplification + BRAF wild-type (1)
KRAS amplification + RAS wild-type (1)
KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)
KRAS mutation + BCL2A1 overexpression (1)
KRAS mutation + CDK9 overexpression + HR positive (1)
KRAS mutation + EGFR amplification (1)
KRAS mutation + ER expression (1)
KRAS mutation + HER-2 positive (1)
KRAS mutation + HR positive (1)
KRAS mutation + PD-L1 underexpression (1)
KRAS mutation + PIK3CA wild-type (1)
KRAS mutation + PTPN11 overexpression (1)
KRAS mutation + TP53 mutation + GNA13 deletion (1)
KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)
KRAS mutation + YKL-40 overexpression (1)
KRAS wild-type + BRAF V600E (1)
KRAS wild-type + NRAS wild-type + MSI-H/dMMR (1)
KRAS mutation + STK11 mutation + AXL expression (1)
MLL-AFF1 fusion + KRAS mutation (1)
MSI-H/dMMR + KRAS G12D (1)
MSI-H/dMMR + KRAS Mutation (1)
MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)
MTAP deletion + KRAS G12C (1)
PD-L1 negative + KRAS G12C (1)
PD-L1 overexpression + KRAS G12C + TP53 mutation (1)
POMK-NRG1 fusion + KRAS mutation (1)
POMK‐NRG1 fusion + KRAS G12D (1)
PTEN deletion + KRAS G12C (1)
RET positive + KRAS G12V (1)
ROS1 fusion + KRAS G12C (1)
STK11 mutation + KRAS mutation + TP53 deletion (1)
STRN-ALK fusion + KRAS G13D (1)
TP53 S12F + KRAS G12D + TMB-L (1)
HER-2 amplification + KRAS G12C (0)
PRMT5 overexpression + KRAS mutation (0)
›
Related tests:
FoundationOne® CDx (110)
therascreen® KRAS RGQ PCR Kit (5)
MI Cancer Seek™
OncoReveal™ Dx Lung and Colon Cancer Assay (O/RDx-LCCA)
FoundationOne® CDx (110)
therascreen® KRAS RGQ PCR Kit (5)
MI Cancer Seek™
OncoReveal™ Dx Lung and Colon Cancer Assay (O/RDx-LCCA)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
KRAS wild-type
Rectal Cancer
KRAS wild-type
Rectal Cancer
panitumumab
Sensitive: A2 - Guideline
panitumumab
Sensitive
:
A2
panitumumab
Sensitive: A2 - Guideline
panitumumab
Sensitive
:
A2
KRAS wild-type
Colon Cancer
KRAS wild-type
Colon Cancer
panitumumab
Sensitive: A2 - Guideline
panitumumab
Sensitive
:
A2
panitumumab
Sensitive: A2 - Guideline
panitumumab
Sensitive
:
A2
KRAS wild-type
Colon Cancer
KRAS wild-type
Colon Cancer
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
KRAS wild-type
Rectal Cancer
KRAS wild-type
Rectal Cancer
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
KRAS wild-type
Ovarian Cancer
KRAS wild-type
Ovarian Cancer
VS-6766 + VS-6063
Sensitive: B - Late Trials
VS-6766 + VS-6063
Sensitive
:
B
VS-6766 + VS-6063
Sensitive: B - Late Trials
VS-6766 + VS-6063
Sensitive
:
B
KRAS wild-type
Pancreatic Ductal Adenocarcinoma
KRAS wild-type
Pancreatic Ductal Adenocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: B - Late Trials
gemcitabine + albumin-bound paclitaxel
Sensitive
:
B
gemcitabine + albumin-bound paclitaxel
Sensitive: B - Late Trials
gemcitabine + albumin-bound paclitaxel
Sensitive
:
B
KRAS wild-type
Colorectal Cancer
KRAS wild-type
Colorectal Cancer
cetuximab
Sensitive: B - Late Trials
cetuximab
Sensitive
:
B
cetuximab
Sensitive: B - Late Trials
cetuximab
Sensitive
:
B
KRAS wild-type
Pancreatic Ductal Adenocarcinoma
KRAS wild-type
Pancreatic Ductal Adenocarcinoma
5-fluorouracil + oxaliplatin
Sensitive: B - Late Trials
5-fluorouracil + oxaliplatin
Sensitive
:
B
5-fluorouracil + oxaliplatin
Sensitive: B - Late Trials
5-fluorouracil + oxaliplatin
Sensitive
:
B
KRAS wild-type
Colorectal Cancer
KRAS wild-type
Colorectal Cancer
panitumumab
Sensitive: B - Late Trials
panitumumab
Sensitive
:
B
panitumumab
Sensitive: B - Late Trials
panitumumab
Sensitive
:
B
KRAS wild-type
Colorectal Cancer
KRAS wild-type
Colorectal Cancer
cetuximab + palbociclib
Sensitive: C2 – Inclusion Criteria
cetuximab + palbociclib
Sensitive
:
C2
cetuximab + palbociclib
Sensitive: C2 – Inclusion Criteria
cetuximab + palbociclib
Sensitive
:
C2
KRAS wild-type
Colorectal Cancer
KRAS wild-type
Colorectal Cancer
bevacizumab
Sensitive: C2 – Inclusion Criteria
bevacizumab
Sensitive
:
C2
bevacizumab
Sensitive: C2 – Inclusion Criteria
bevacizumab
Sensitive
:
C2
KRAS wild-type
Biliary Tract Cancer
KRAS wild-type
Biliary Tract Cancer
panitumumab
Sensitive: C2 – Inclusion Criteria
panitumumab
Sensitive
:
C2
panitumumab
Sensitive: C2 – Inclusion Criteria
panitumumab
Sensitive
:
C2
KRAS wild-type
Colorectal Cancer
KRAS wild-type
Colorectal Cancer
CPGJ-602
Sensitive: C2 – Inclusion Criteria
CPGJ-602
Sensitive
:
C2
CPGJ-602
Sensitive: C2 – Inclusion Criteria
CPGJ-602
Sensitive
:
C2
KRAS wild-type
Colorectal Cancer
KRAS wild-type
Colorectal Cancer
SCT200
Sensitive: C2 – Inclusion Criteria
SCT200
Sensitive
:
C2
SCT200
Sensitive: C2 – Inclusion Criteria
SCT200
Sensitive
:
C2
KRAS wild-type
Colorectal Cancer
KRAS wild-type
Colorectal Cancer
panitumumab + cabozantinib tablet
Sensitive: C3 – Early Trials
panitumumab + cabozantinib tablet
Sensitive
:
C3
panitumumab + cabozantinib tablet
Sensitive: C3 – Early Trials
panitumumab + cabozantinib tablet
Sensitive
:
C3
KRAS wild-type
Colorectal Cancer
KRAS wild-type
Colorectal Cancer
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
KRAS wild-type
Pancreatic Ductal Adenocarcinoma
KRAS wild-type
Pancreatic Ductal Adenocarcinoma
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
durvalumab + tremelimumab
Sensitive
:
C3
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
durvalumab + tremelimumab
Sensitive
:
C3
KRAS wild-type
Non Small Cell Lung Cancer
KRAS wild-type
Non Small Cell Lung Cancer
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
KRAS wild-type
Colorectal Cancer
KRAS wild-type
Colorectal Cancer
EGFR inhibitor
Sensitive: C3 – Early Trials
EGFR inhibitor
Sensitive
:
C3
EGFR inhibitor
Sensitive: C3 – Early Trials
EGFR inhibitor
Sensitive
:
C3
KRAS wild-type
Colorectal Cancer
KRAS wild-type
Colorectal Cancer
VEGF inhibitor
Sensitive: C3 – Early Trials
VEGF inhibitor
Sensitive
:
C3
VEGF inhibitor
Sensitive: C3 – Early Trials
VEGF inhibitor
Sensitive
:
C3
KRAS wild-type
Pancreatic Cancer
KRAS wild-type
Pancreatic Cancer
nimotuzumab
Sensitive: C3 – Early Trials
nimotuzumab
Sensitive
:
C3
nimotuzumab
Sensitive: C3 – Early Trials
nimotuzumab
Sensitive
:
C3
KRAS wild-type
Acute Myelogenous Leukemia
KRAS wild-type
Acute Myelogenous Leukemia
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
KRAS wild-type
Glioblastoma
KRAS wild-type
Glioblastoma
panitumumab
Sensitive: C3 – Early Trials
panitumumab
Sensitive
:
C3
panitumumab
Sensitive: C3 – Early Trials
panitumumab
Sensitive
:
C3
KRAS wild-type
Colorectal Cancer
KRAS wild-type
Colorectal Cancer
MM-121
Sensitive: D – Preclinical
MM-121
Sensitive
:
D
MM-121
Sensitive: D – Preclinical
MM-121
Sensitive
:
D
KRAS wild-type
Ovarian Serous Adenocarcinoma
KRAS wild-type
Ovarian Serous Adenocarcinoma
VS-6766 + VS-4718
Sensitive: D – Preclinical
VS-6766 + VS-4718
Sensitive
:
D
VS-6766 + VS-4718
Sensitive: D – Preclinical
VS-6766 + VS-4718
Sensitive
:
D
KRAS wild-type
Ovarian Serous Adenocarcinoma
KRAS wild-type
Ovarian Serous Adenocarcinoma
VS-4718
Sensitive: D – Preclinical
VS-4718
Sensitive
:
D
VS-4718
Sensitive: D – Preclinical
VS-4718
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login